μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence
By L. Bohn, R. Gainetdinov, F. Lin, R. J. Lefkowitz, M. Caron. Nature, 2000
828 citations recorded by the source corpus.
Subfields: Cellular and Molecular Neuroscience, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/2ce3e498b18dfbb12fd79237ff29a78666be43c9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cellular and Molecular Neuroscience
In Molecular Biology
Citations in the corpus
- Regulation of µ-Opioid Receptors: Desensitization, Phosphorylation, Internalization, and Tolerance (2013, background): “, 2011) and for GTPgS binding in brainstem tissue (Bohn et al., 2000) are consistent with this idea, but tolerance to other agonists has not yet been tested.”
- The Physiology, Signaling, and Pharmacology of Dopamine Receptors (2011, background): “In an initial study, -arrestin 2-deficient mice were found to exhibit enhanced morphine-induced analgesia compared with WT mice, which indicates that -arrestin 2 plays an important role in -opioid receptor desensitization (Bohn et al., 1999, 2000, 2003, 2004).”
- The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. (2002, background): “…with an inability to develop tolerance to the antinociceptive effects of morphine, but does not prevent the development of opioid dependence (Bohn et al., 2000). β-arrestins in GPCR sequestration Internalization of GPCRs, also termed receptor sequestration or endocytosis, occurs more slowly…”
- A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine (2013, background): “While these facets of MOR pharmacology will be explored with TRV130 in future studies, several of the previous studies of morphine in b-arrestin-2 knockout mice suggest that TRV130 may have reduced potential for addiction and analgesic tolerance (Bohn et al., 2000; Bohn et al., 2003; Raehal and Bohn”